Recent Finacing
Recent Raise
Allterum Therapeutics is a Houston biopharmaceutical company developing 4A10, an NCI‑licensed anti‑CD127 monoclonal antibody advancing to Phase I/IIA for relapsed/refractory ALL with plans for label expansion.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Allterum Therapeutics.
